100 related articles for article (PubMed ID: 17018393)
1. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England.
Phekoo KJ; Richards MA; Møller H; Schey SA;
Haematologica; 2006 Oct; 91(10):1400-4. PubMed ID: 17018393
[TBL] [Abstract][Full Text] [Related]
2. The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens.
Mundt KA; Dell LD; Boffetta P; Beckett EM; Lynch HN; Desai VJ; Lin CK; Thompson WJ
BMC Cancer; 2021 Mar; 21(1):227. PubMed ID: 33676443
[TBL] [Abstract][Full Text] [Related]
3. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study.
Maynadié M; De Angelis R; Marcos-Gragera R; Visser O; Allemani C; Tereanu C; Capocaccia R; Giacomin A; Lutz JM; Martos C; Sankila R; Johannesen TB; Simonetti A; Sant M;
Haematologica; 2013 Feb; 98(2):230-8. PubMed ID: 22983589
[TBL] [Abstract][Full Text] [Related]
4. Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network 2004-15.
Roman E; Smith A; Appleton S; Crouch S; Kelly R; Kinsey S; Cargo C; Patmore R
Cancer Epidemiol; 2016 Jun; 42():186-98. PubMed ID: 27090942
[TBL] [Abstract][Full Text] [Related]
5. Real-world data of MDS and CMML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
Usuki K; Ohtake S; Honda S; Matsuda M; Wakita A; Nawa Y; Takase K; Maeda A; Sezaki N; Yokoyama H; Takada S; Hirano D; Tomikawa T; Sumi M; Yano S; Handa H; Ota S; Fujita H; Fujimaki K; Mugitani A; Kojima K; Kajiguchi T; Fujimoto K; Asou N; Usui N; Ishikawa Y; Katsumi A; Matsumura I; Miyazaki Y; Kiyoi H
Int J Hematol; 2024 Feb; 119(2):130-145. PubMed ID: 38091231
[TBL] [Abstract][Full Text] [Related]
6. Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
Usuki K; Ohtake S; Honda S; Matsuda M; Wakita A; Nawa Y; Takase K; Maeda A; Sezaki N; Yokoyama H; Takada S; Hirano D; Tomikawa T; Sumi M; Yano S; Handa H; Ota S; Fujita H; Fujimaki K; Mugitani A; Kojima K; Kajiguchi T; Fujimoto K; Asou N; Usui N; Ishikawa Y; Katsumi A; Matsumura I; Kiyoi H; Miyazaki Y
Int J Hematol; 2024 Jan; 119(1):24-38. PubMed ID: 38015362
[TBL] [Abstract][Full Text] [Related]
7. Concurrent chronic myelomonocytic leukemia and gastric carcinoma: a case report and literature review.
Fang C; Chen Z; Li J; Yu L; Wang L
AME Case Rep; 2023; 7():37. PubMed ID: 37942038
[TBL] [Abstract][Full Text] [Related]
8. Real-world data on efficacy and safety of azacitidine therapy in chronic myelomonocytic leukemia in China: results from a multicenter, retrospective study.
Xu Y; Guo R; Miao M; Zhang G; Lan J; Jin J
Invest New Drugs; 2022 Oct; 40(5):1117-1124. PubMed ID: 35834039
[TBL] [Abstract][Full Text] [Related]
9. Mouse Models of CMML.
Belotserkovskaya E; Demidov O
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768940
[TBL] [Abstract][Full Text] [Related]
10. Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?
Ono T
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680265
[TBL] [Abstract][Full Text] [Related]
11. Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.
Renneville A; Patnaik MM; Chan O; Padron E; Solary E
Leukemia; 2021 Oct; 35(10):2739-2751. PubMed ID: 34175902
[TBL] [Abstract][Full Text] [Related]
12. Philadelphia-negative myeloproliferative neoplasms among Kuwaiti Nationals.
Alshemmari S; Almazyad M; Alwehaib A; Ameen R
Cancer Med; 2021 Jan; 10(1):365-371. PubMed ID: 33280271
[TBL] [Abstract][Full Text] [Related]
13. Myeloid Leukemias: A Glance at Middle Eastern Centers.
Khaled SA; Nabih O; Abdel Aziz NM; Mahran DG
J Blood Med; 2019; 10():425-433. PubMed ID: 31908557
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-27 and interleukin-35 in de novo acute myeloid leukemia: expression and significance as biological markers.
Ahmed HA; Maklad AM; Khaled SA; Elyamany A
J Blood Med; 2019; 10():341-349. PubMed ID: 31686937
[TBL] [Abstract][Full Text] [Related]
15. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
Front Immunol; 2018; 9():2587. PubMed ID: 30487792
[TBL] [Abstract][Full Text] [Related]
16. The incidence of acute myeloid leukemia in Calgary, Alberta, Canada: a retrospective cohort study.
Shysh AC; Nguyen LT; Guo M; Vaska M; Naugler C; Rashid-Kolvear F
BMC Public Health; 2017 Aug; 18(1):94. PubMed ID: 28774275
[TBL] [Abstract][Full Text] [Related]
17. CMML: Clinical and molecular aspects.
Itzykson R; Duchmann M; Lucas N; Solary E
Int J Hematol; 2017 Jun; 105(6):711-719. PubMed ID: 28455647
[TBL] [Abstract][Full Text] [Related]
18. Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations.
Blum S; Martins F; Alberio L
J Blood Med; 2016; 7():205-215. PubMed ID: 27729820
[TBL] [Abstract][Full Text] [Related]
19. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Common Chromosomal Translocations and Their Frequencies in Acute Myeloid Leukemia Patients of Northwest Iran.
Amanollahi Kamaneh E; Shams Asenjan K; Movassaghpour Akbari A; Akbarzadeh Laleh P; Chavoshi H; Eivazi Ziaei J; Nikanfar A; Asvadi Kermani I; Esfahani A
Cell J; 2016; 18(1):37-45. PubMed ID: 27054117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
